National Glaucoma Research - Current Award

	David Calkins, Ph.D. Vanderbilt University Medical Center Nasville, TN Title: TRPV1: A Novel Neuroprotective Target in Glaucoma Non-Technical Title: Targeting Neurobiological Sensitivity to Pressure in Glaucoma Acknowledgements: Recipient of the Thomas R. Lee award for National Glaucoma Research Duration: April 1, 2008 - March 31, 2010 Award Type: Standard Award Amount: $100,000
Summary: This research is aimed at understanding how optic nerve fibers respond to eye pressure and whether blunting this response could prevent vision loss in glaucoma. The study will also help identify new drugs to reduce optic nerve loss in glaucoma by making its fibers insensitive to eye pressure.

Details:

Glaucoma is the leading cause of irreversible blindness worldwide and is estimated to afflict some 80 million people by 2020. Most people think of glaucoma as a disease about pressure in the eye, because high pressure is associated with the disease and lowering pressure often is helpful for slowing vision loss in glaucoma. In fact, glaucoma is irreversible because it damages the fibers of the optic nerve, which is part of the brain and therefore limited in its ability to heal. Our research is important because it is the first attempt to understand how these fibers respond to pressure in the eye and whether blunting this response could prevent vision loss in glaucoma. Our team is comprised of neurobiologists with expertise in how nerve fibers respond to pressure. Thus, our research will help identify new drugs that will reduce the loss of the optic nerve in glaucoma by making its fibers insensitive to pressure in the eye.